Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04827745 · ClinicalTrials.gov registry record · Phase 2
Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL
A Phase 2 study of Mixed Phenotype Acute Leukemia (MPAL) and Measurable Residual Disease (MRD), sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT04827745: Completed Phase 2 study of Mixed Phenotype Acute Leukemia (MPAL) and Measurable Residual Disease (MRD), sponsored by University of Maryland, Baltimore.
NCT04827745 is a Phase 2 study of Mixed Phenotype Acute Leukemia (MPAL) and Measurable Residual Disease (MRD) that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04827745, a Phase 2 study of Mixed Phenotype Acute Leukemia (MPAL) and Measurable Residual Disease (MRD), has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a research study to find out if a drug called blinatumomab is effective for treating patients with relapsed or refractory (R/R) or measurable residual disease (MRD) CD19-positive mixed phenotypic acute leukemia (MPAL). Measurable Residual Disease (MRD) means that there are a small number of cancer cells remaining after treatment
Primary Outcome
The rate of achievement of CR+CRh after the first 2 cycles of blinatumomab in Cohort A subjects
Conditions Studied
Interventions
- DRUG BLINCYTO (Blinatumomab)
Study Locations (1)
Maryland
- Greenebaum Cancer Center at University of Maryland Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-06-11 |
| Est. Completion | 2025-05-22 |
| Phase | Phase 2 |
What the finished NCT04827745 record still lists
NCT04827745 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Mixed Phenotype Acute Leukemia (MPAL) appearing as the primary indexed condition, and to 1 intervention - of which BLINCYTO (Blinatumomab) is the first listed.
NCT04827745 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04827745 about?
NCT04827745 is a clinical study titled "Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL". This is a research study to find out if a drug called blinatumomab is effective for treating patients with relapsed or refractory (R/R) or measurable residual disease (MRD) CD19-positive mixed phenotypic acute leukemia (MPAL). Measurable Residual Disease (MRD) means that there are a small number of ...
What is the current status of trial NCT04827745?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2021-06-11. Estimated completion is 2025-05-22.
What conditions does trial NCT04827745 study?
This clinical trial studies the following conditions: Mixed Phenotype Acute Leukemia (MPAL), Measurable Residual Disease (MRD).
What interventions are being tested in trial NCT04827745?
The interventions under investigation include: BLINCYTO (Blinatumomab) (DRUG).
Who is sponsoring clinical trial NCT04827745?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04827745 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mixed Phenotype Acute Leukemia (MPAL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04827745's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI